Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion
Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100...
NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis
The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...
Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines
US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global...
WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services
China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed...
Eppendorf to Start Construction on New Shanghai Production Site
Germany-based life sciences service provider Eppendorf is set to begin work on a new production...
InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics
US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based...
Brii Biosciences Publishes Positive Phase II Results for HBV Treatment
China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...
Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...
Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Hygea Medtech Secures Series D Funding for Oncology Device Expansion
Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...